Relief

Relief Therapeutics Advances Publication of 2025 Half-Year Report

GENEVA (Aug. 11, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a b...

Relief

Relief Therapeutics Announces Results of Annual General Meeting

hareholders approved all proposals by a large majority GENEVA (June 12, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: ...

Relief

Relief Therapeutics Publishes 2025 Annual General Meeting Agenda

Relief Therapeutics today published the agenda for its 2025 Annual General Meeting (AGM) of shareholders, to be held ...

Relief

Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011

Relief Therapeutics today announced that the European Patent Office (EPO) has issued a Decision to Grant for its pate...

Relief

Relief Therapeutics Provides Update on Potential Transaction with Renexxion

Relief Therapeutics today provided an update on the potential reverse merger with Renexxion, Inc. (Renexxion), a priv...

Relief

Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial

Relief Therapeutics today announced the full readout and compelling results from the clinical trial evaluating PKU GO...